HB Wealth Management LLC Boosts Stock Position in Becton, Dickinson and Company $BDX

HB Wealth Management LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 42.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,650 shares of the medical instruments supplier’s stock after buying an additional 9,678 shares during the quarter. HB Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $6,111,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. SOA Wealth Advisors LLC. raised its position in shares of Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the last quarter. Bell Investment Advisors Inc raised its holdings in Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 128 shares during the last quarter. Bank of Jackson Hole Trust lifted its stake in shares of Becton, Dickinson and Company by 85.6% in the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 95 shares in the last quarter. CVA Family Office LLC grew its holdings in shares of Becton, Dickinson and Company by 79.5% during the second quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 97 shares during the last quarter. Finally, CoreFirst Bank & Trust bought a new stake in shares of Becton, Dickinson and Company during the second quarter valued at approximately $38,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Trading Up 1.2%

Shares of NYSE:BDX opened at $205.14 on Friday. The stock’s 50-day simple moving average is $192.63 and its two-hundred day simple moving average is $187.89. The stock has a market capitalization of $58.45 billion, a price-to-earnings ratio of 35.19, a PEG ratio of 2.24 and a beta of 0.23. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were issued a dividend of $1.05 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend was Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is presently 72.04%.

Wall Street Analysts Forecast Growth

Several analysts have commented on BDX shares. Jefferies Financial Group increased their target price on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Royal Bank Of Canada increased their price objective on Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Bank of America lifted their price objective on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a report on Monday. Stifel Nicolaus upped their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Argus lifted their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Four equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $207.64.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 629 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total transaction of $123,302.87. Following the transaction, the executive vice president directly owned 13,105 shares in the company, valued at $2,568,973.15. This represents a 4.58% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 1,052 shares of company stock valued at $201,235. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.